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Abstract
Background. Little information is available on a long-
term follow-up in Bartter syndrome type I and II.
Methods. Clinical presentation, treatment and long-term
follow-up (5.0–21, median 11 years) were evaluated in
15 Italian patients with homozygous (n = 7) or compound
heterozygous (n = 8) mutations in the SLC12A1 (n = 10) or
KCNJ1 (n = 5) genes.
Results. Thirteen new mutations were identified. The
15 children were born pre-termwith a normal for gestational
age body weight. Medical treatment at the last follow-up
control included supplementation with potassium in 13,
non-steroidal anti-inflammatory agents in 12 and gastropro-
tective drugs in five patients. At last follow-up, body weight
and height were within normal ranges in the patients. Glo-
merular filtration rate was <90 mL/min/1.73 m2 in four
patients (one of them with a pathologically increased uri-
nary protein excretion). In three patients, abdominal ul-
trasound detected gallstones. The group of patients with
antenatal Bartter syndrome had a lower renin ratio (P <
0.05) and a higher standard deviation score (SDS) for
height (P < 0.05) than a previously studied group of pa-
tients with classical Bartter syndrome.
Conclusions. Patients with Bartter syndrome type I and II
tend to present a satisfactory prognosis after a median fol-
low-up of more than 10 years. Gallstones might represent a
new complication of antenatal Bartter syndrome.
Keywords: Bartter syndrome; cholelithiasis; growth retardation; KCNJ1
gene; SLC12A1 gene
Introduction
Bartter syndrome type I (BS I) and type II (BS II) are salt-
wasting renal tubular disorders that are clinically character-
ized by polyhydramnios leading to premature delivery,
marked polyuria and a tendency towards nephrocalcinosis
[1,2]. Loss-of-function mutations either in the furosemide-
sensitive sodium–potassium–chloride cotransporter gene
(SLC12A1; BS I, OMIM 601678) or in the inwardly rectify-
ing potassium channel ROMK gene (KCNJ1; BS II, OMIM
241200) have been identified in the vast majority of patients
with this autosomal recessive disorder [3,4]. Mutations in
the CLCNKB chloride channel gene (Bartter syndrome type
III also defined as classical Bartter syndrome—OMIM
607364) aswell as in the BSNDgene (Bartter syndrome form
associated with sensorineural deafness—Bartter type IV—
OMIM 602522) are also sometimes responsible for an iden-
tical clinical phenotype but will not be treated in this report.
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Little information is currently available on the disease
course of these patients [5–7]. The purpose of the current
analysis was to shed additional light on clinical presenta-
tion, initial diagnostic pitfalls and especially follow-up in
15 patients with bi-allelic mutations either in the SLC12A1
or in the KCNJ1 genes. The outcome in patients with an-
tenatal Bartter syndrome was also compared with that ob-
served in a recently published group of patients affected
with classical Bartter syndrome [8].
Materials and methods
Among 34 patients with the clinical and biochemical diagnosis of antena-
tal Bartter syndrome on follow-up at our institutions, 15 presented homo-
zygous or compound heterozygous mutations in the SLC12A1 or KCNJ1
genes together with a clinical–biochemical follow-up of 5 years or more.
Thirteen patients with antenatal Bartter syndrome presenting bi-allelic
mutations and a shorter follow-up and another six patients with only
one mutation detected were not further analysed in this study. The clinical
features at presentation and at the last follow-up control were collected for
these patients. The glomerular filtration rate was estimated from height
and creatinine using the original Schwartz formula [9]. Since plasma renin
(or plasma renin activity) and aldosterone were evaluated in different lab-
oratories, we refer to their results either as renin ratio or aldosterone ratio.
These indexes were calculated by dividing the individual renin (either
plasma renin activity or active renin level) or aldosterone value by the
corresponding upper reference value [8]. Renal ultrasound imaging was
performed at diagnosis and at last follow-up in all patients. The last renal
ecography was also evaluated for the grade of medullary nephrocalcinosis
by three different paediatricians. The grading scale for medullary nephro-
calcinosis was as follows: grade 1, mild increase in the echogenicity
around the border of the medullary pyramid; grade 2, mild diffuse in-
crease in the echogenicity of the entire medullary pyramid; grade 3, great-
er or more homogeneous increase in the echogenicity of the entire
medullary pyramid. In some patients, follow-up imaging included also
the evaluation of liver and gallbladder.
The non-parametric two-tailed Mann–Whitney–Wilcoxon test for two
independent samples was used for analysis. Statistical significance was
defined as a P-value of <0.05.
Genomic DNA was extracted from peripheral white blood cells using
standard methods. All coding sequences of SLC12A1 and KCNJ1 genes
with their intron/exon boundaries were amplified by means of PCR us-
ing specific primer pairs. Direct sequencing of the purified PCR pro-
ducts was then performed bidirectionally by the dye terminator cycle
sequencing method (Applied Biosystem, Foster City, CA, USA) loaded
on a 16-capillary ABI Prism 3100 genetic analyser (Applied Biosystem,
Foster City, CA, USA) and analysed with the Sequencing Analysis 3.7
software. Mutations were discerned from polymorphisms by demonstra-
tion of their absence in 100 control chromosomes. The nomenclature is
based on the recommendations of the Human Genomic Variant Society
starting with the nucleotide 1 of the start codon (ATG) at cDNA level.
A written informed consent had been obtained from all patients and
their family members.
Results
Molecular findings
The 15 patients with homozygous or compound heterozy-
gous mutations considered in this study (8 female and 7
male subjects) belong to 15 non-consanguineous Italian
families (Table 1). The results of direct sequencing of
the SLC12A1 and KCNJ1 genes revealed 13 new muta-
tions and 7 previously described mutations. Patient 3,
who carried a compound heterozygous mutation, had been
previously described as a single heterozygous mutation
[10]. Among the 10 patients presenting SLC12A1 gene Ta
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mutations, 6 were compound heterozygous and 4 homozy-
gous. Among the five patients presenting KCNJ1 gene mu-
tations, three were homozygous and two compound
heterozygous. The homozygous mutations were confirmed
on both the parents of the patients in order to exclude the
presence of a heterozygous deletion of corresponding
exons. The genetic abnormalities described were not pres-
ent in a sample of 50 healthy controls (100 chromosomes
investigated).
Initial findings
History of premature delivery, polyhydramnios and poly-
uria was present in all patients, but the final clinical diag-
nosis of Bartter syndrome was made before the age of
26 months in 12 patients (Figure 1). Birth weight was never
less than 2 standard deviation scores (SDS) below the mean
for gestational age. The birth weight SDS was on the aver-
age higher (P < 0.05) in BS I than in BS II patients. The di-
agnosis of diabetes insipidus was initially suspected in two
BS I patients who presented with hypernatraemia and that of
pseudohypoaldosteronism in the two BS I patients who pre-
sented with plasma potassium >6.0 mmol/L. In one of them
(Patient 7), acute renal failure was also present.
The overall median plasma sodium was 137 mmol/L
(range 125–156), and it was increased in three and mildly
decreased in two patients (Figure 1). The overall median
plasma chloride was 98 mmol/L (range 84–107), and it
was decreased in four patients. Plasma potassium was re-
duced in eight but normal (n = 1) or even increased (n =
1) in BS I patients (median 2.7, range 1.9–6.3 mmol/L).
On the contrary, the level of this electrolyte was mildly re-
duced in one but normal (n = 1) or even increased (n = 3) in
four of the five BS II patients (median 5.7, range 3.3–
6.7 mmol/L): the difference between BS I and BS II was
significant (P < 0.03). Hyperbicarbonataemia (HCO3
−
>25 mmol/L) was similarly frequent both in patients with
BS I (8 of 10 patients) as well as in patients with BS II. The
overall median plasma bicarbonate was 27 mmol/L (range
25–32). No hypomagnesaemia was noted in the 15 patients,
and the overall median plasma magnesium level was
2.4 mg/dL (range 1.9–2.8). Aldosterone ratio was increased
in all but two patients, and renin ratio was increased in all
patients. Plasma creatinine was moderately increased in 1
of the neonates affected with Bartter type I syndrome
(Patient 7) and normal in the remaining 14 patients
(Figure 1).
Renal ultrasound disclosed signs of medullary nephro-
calcinosis in all patients with the exception of one BS II
patient (Patient 11). The degree of nephrocalcinosis at
diagnosis and the urinary calcium excretion were not
evaluated.
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Fig. 1. Age at the final diagnosis and the initial clinical and laboratory data in 15 patients with homozygous or heterozygous mutations in the SLC12A1
(BS I; closed symbols) or KCNJ1 (BS II; open symbols) genes. Plasma bicarbonate was not assessed at presentation in one patient affected with BS II.
Birth weight SDS was significantly higher (P < 0.05) and plasma potassium lower (P < 0.03) in BS I than in BS II. The frames denote the reference
ranges.
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Follow-up
Clinical and biochemical data at the last follow-up are giv-
en in Figure 2. None of the 15 patients suffered from overt
underweight or small stature. Plasma sodium and chloride
were within the normal ranges in all patients with the ex-
ception of one BS I patient who presented with mild hypo-
chloraemia. The overall median plasma sodium was
139 mmol/L (range 137–145) and plasma chloride
101 mmol/L (range 93–108), respectively. Plasma potassi-
um was reduced in 6 of the 10 BS I patients (median 3.1,
range 2.5–4.3 mmol/L) and within the normal ranges in all
BS II patients (median 3.9, range 3.6–4.1 mmol/L). How-
ever, the difference in plasma potassium between these two
groups did not reach significant values. Hyperbicarbona-
taemia was noted in 9 of the 10 BS I patients (median
27, range 25–31 mmol/L) and in 2 of the 5 BS II patients
(median 25, range 24–26 mmol/L). The plasma total mag-
nesium level was never reduced in the 15 patients. Aldo-
sterone ratio was normalized in seven patients: four with
BS I and three with BS II. Renin ratio was normalized
in four patients. Glomerular filtration rate was >90 mL/
min/1.73 m2 in 11 and mildly reduced in 4 patients,
2 patients each with BS I and BS II. Moderate glomerular
proteinuria (∼1 g/day) was noted in one of the patients
with a reduced glomerular filtration rate (Patient 5).
The urinary molar calcium/creatinine ratio was evaluat-
ed at the last clinical control in 8 out the 10 patients with
BS I and in 3 out of 5 patients with BS II: this parameter
was increased (>0.60) in 10 of the 11 aforementioned
patients.
As at presentation, renal ultrasound disclosed signs of
nephrocalcinosis in all patients with the exception of Pa-
tient 11. Nephrocalcinosis was classified as follows: five
BS I patients presented with grade 2 and five with grade
3; 2 BS II patients presented with grade 1 and two with
grade 3. At least one complete abdominal ultrasound
was performed in 10 patients: in three patients, two with
BS I (Patient 8 and 9) and one with BS II (Patient 13),
asymptomatic gallstones were detected (1–3 stones per pa-
tient with a diameter of ≤5 mm). Long-term parenteral nu-
trition, a recognized cause of gallstones, had been
performed in Patient 8. The age at detection of cholelithi-
asis was 2.2 and 8.7 years in BS I and 2.9 years in BS II. A
persistent cholelithiasis was demonstrated on follow-up in
Patient 9 and 13. No corresponding follow-up is so far
available for Patient 8.
All patients had normal blood pressure, and no hearing
loss during the follow-up period was detected. The neuro-
developmental assessment was normal in the patients with
the exception of Patient 15 who presented a mild left hemi-
paresis secondary to neonatal ischaemic brain damage.
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Fig. 2. Clinical and laboratory features in 15 patients with homozygous or heterozygous mutations in SLC12A1 (BS I; closed symbols) or in KCNJ1
(BS II; open symbols) genes 5.0–21, median 11 years after diagnosis. No significant difference was noted between BS I and BS II syndromes. The
frames denote the reference ranges.
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Medical treatment at the last follow-up control included
the non-steroidal anti-inflammatory agent indomethacin in
11 patients (from 0.2 to 2.2, median 0.9 mg/kg body
weight daily), flurbiprofen in one patient, gastroprotective
agents in five patients (ranitidine, n = 4; lansoprazole, n =
1) and spironolactone associated with hydrochlorothiazide
in one patient. Supplementation with potassium chloride
was administered in 13 patients (from 0.5 to 2.3 mmol/
kg body weight daily). Patient 3 developed a peptic ulcer
at 6 years of age on indomethacin 2.0 mg/kg body weight
daily. This agent was reintroduced 2 years later without re-
currence of the peptic disease. In Patient 2, a growth hor-
mone deficiency was demonstrated on follow-up, and
treatment with recombinant human growth hormone was
introduced during 3 years.
Comparison with classical Bartter syndrome (BS III)
The findings at follow-up in our 15 patients with BS I and
BS II were compared with those noted in a group of 13
patients affected with BS III recently as reported by some
members of our group [8]. No differences between the
two groups were noted with respect to the blood levels
of sodium, potassium, chloride and bicarbonate; the
aldosterone ratio; and the glomerular filtration rate. The
plasma renin ratio was significantly (P < 0.05) lower in
the group of patients with BS I and BS II as compared with
BS III (Figure 3). The height SDS was significantly
(P < 0.05) higher in BS I–II types than in BS III. No signifi-
cant correlation between renin ratio and height SDSwas not-
ed in BS III, in BS I–II types or in the cumulated group of
patients with either BS III or BS I–II types.
Discussion
The present study describes the genetic findings, the initial
clinical and laboratory characteristics, and especially, the
outcome and current management in 15 patients with ho-
mozygous or compound heterozygous mutations in the
SLC12A1 and KCNJ1 genes after a median follow-up of
11 years. BS I patients showed mutations that were spread
all over the SLC12A1 gene; on the contrary, all BS II pa-
tients showed mutations in exon 5 of the KCNJI gene, as
mainly observed [3–7]. The seven new mutations in the
SLC12A1 and five out of the six mutations in the KCNJ1
were missense. The 13 new missense variants are likely
pathogenic, since they substitute highly conserved amino
acids in both the genes and were not detected in 100 healthy
chromosomes.
The p.Arg116His mutation identif ied in Patient 4,
which has also been described as a single-nucleotide poly-
morphism (rs34819316), was detected in another homozy-
gous patient not included in this study. So far, functional
studies have never been performed on this variant unequiv-
ocally demonstrating its polymorphic nature.
It is assumed that patients affected by antenatal Bartter
syndrome are often born prematurely or with a small for
gestational age birth weight [5–7]. The present survey con-
firms that these patients are born prematurely after a preg-
nancy complicated by polyhydramnios but with a normal
for gestational age weight, therefore excluding major intra-
uterine growth retardation in these conditions (however,
the birth weight SDS is lower in BS II than in BS I pa-
tients). Patients with BS I and BS II present with similar
clinical and laboratory findings with the exception of po-
tassium level, which is often reduced in BS I but normal or
even increased in BS II [5–7].
Since hypokalaemia and metabolic alkalosis, two pecu-
liar biochemical findings in Bartter syndrome, are often
absent at presentation in the antenatal form of this syn-
drome, other conditions including diabetes insipidus (in
subjects with hypernatraemia) or pseudohypoaldosteron-
ism (in patients with hyperkalaemia) are initially suspected
in some cases [5,7,11].
Patients with antenatal Bartter syndrome are managed
with potassium chloride and non-steroidal anti-inflamma-
tory agents, mostly indomethacin. The present experience
confirms that, in patients affected by hypokalaemic salt-
losing tubulopathies, gastrointestinal side effects of non-
steroidal anti-inflammatory agents are rather rare and not
severe [5,8,12]. This observation is likely related to the
lower dose of indomethacin (on average 0.9 mg/kg/body
weight daily) as compared with other studies [5,7,12]. Ob-
viously, the risks associated with a suboptimal correction
of hypokalaemia must be balance against the risks of high-
dose therapy with indomethacin.
In our antenatal Bartter patients, both the neurodevelop-
mental outcome and the somatic growth are almost always
normal. In salt-wasting renal tubular disorders, somatic
growth retardation is common and traditionally causally
linked among others with extracellular fluid volume deple-
tion [13]. The present data with a better growth in BS I and
BS II than in BS III and with a higher renin ratio, a recog-
nized marker of fluid volume depletion, in BS III than in BS
I and BSII support the aforementioned link between growth
retardation and fluid volume depletion in the various forms
of Bartter syndrome. Potassium deficiency may also impair
the metabolism of growth hormone [14]; however, the sim-
-4.0
-3.0
-2.0
-1.0
0.0
1.0
2.0
Body Height
(SDS)
2
4
6
Renin
Ratio
10
8
P<0.05 P<0.05
Bartter syndrome type I or II Bartter syndrome type III
Fig. 3. Body height SDS and renin ratio in 15 patients with BS I or
BS II (closed symbols) 5.0–21, median 11 years after diagnosis, and in
13 patients affected with BS III (open symbols) 5.0–24, median 14 years
after diagnosis [8]. Height SDS was significantly higher (P < 0.05) and
plasma renin ratio lower (P < 0.05) in BS I and BS II syndromes than in
BS III. The frames denote the reference ranges.
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ilar potassium level in antenatal and in classical Bartter syn-
drome may suggest that potassium does not account for
growth retardation in classical Bartter syndrome.
A glomerular filtration rate of <90 mL/min/1.73 m2,
sometimes associated with overt proteinuria, was noted
on follow-up in approximately one quarter of our patients.
Nephrocalcinosis is a possible explanation for these obser-
vations. Prolonged hypokalaemia, which can lead to inter-
stitial fibrosis and tubular atrophy, is a further possible
cause [15]. Finally, non-steroidal anti-inflammatory agents
have also been associated with reduced renal function
[16]. However, in antenatal Bartter syndrome, the use of
indomethacin is not related to any relevant lesion on renal
biopsy [5].
We were surprised by the fact that three patients with
antenatal Bartter syndrome developed gallstones, confirm-
ing a recent case report [17]. Possible explanations are that
these patients are born prematurely, that they present with
laboratory characteristics, which may be mimicked by
medication with loop diuretics, and that both prematurity
and long-term administration of loop diuretics predispose
to gallbladder stone formation in childhood [18]. Alterna-
tively, in these patients, the process of gallstone formation
might result from an altered function of either the sodium–
potassium–chloride cotransporter or the channel ROMK
within the hepatobiliary system.
In conclusion, our patients with homozygous or com-
pound heterozygous mutations in the SLC12A1 or KCNJ1
genes managed with potassium chloride and indomethacin
present a satisfactory somatic growth after a median follow-
up of 11 years. Some impairment of kidney function is ob-
served in approximately one quarter of the patients. Finally,
a large subset of these patients develops gallbladder stones.
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